Advanced search
Publication Cover
Expert Review of Medical Devices Volume 10, 2013 - Issue 4
Submit an article Journal homepage
102
Views
1
CrossRef citations to date
0
Altmetric
Review

Radiofrequency ablation in the management of Barrett’s esophagus: present role and future perspective

Ashwin A Kurian Providence Portland Cancer Center, 4805 NE Glisan Street, 6N60, Providence Cancer Center, Portland, OR 97213, USA; Providence Portland Cancer Center, 4805 NE Glisan Street, 6N60, Providence Cancer Center, Portland, OR 97213, USA
&
Lee L Swanström Oregon Clinic GMIS Division, 4805 NE Glisan Street, 6N60, Providence Cancer Center, Portland, OR 97213, USA. [email protected]; Oregon Clinic GMIS Division, 4805 NE Glisan Street, 6N60, Providence Cancer Center, Portland, OR 97213, USA. [email protected]
Pages 509-517 | Published online: 09 Jan 2014

References

  • Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol. Biomarkers Prev. 19(6), 1468–1470 (2010).
  • Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl Cancer Inst. 97(2), 142–146 (2005).
  • Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 120(7), 1607–1619 (2001).
  • Overholt BF, Lightdale CJ, Wang KK et al.; International Photodynamic Group for High-Grade Dysplasia in Barrett’s Esophagus. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized Phase III trial. Gastrointest. Endosc. 62(4), 488–498 (2005).
  • Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 95(7), 1669–1676 (2000).
  • Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett’s high-grade dysplasia. Am. J. Gastroenterol. 95(8), 1888–1893 (2000).
  • Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N. Engl. J. Med. 360(22), 2277–2288 (2009).
  • Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia. Am. J. Gastroenterol. 95(11), 3089–3096 (2000).
  • Konda VJ, Ross AS, Ferguson MK et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett’s esophagus overestimated? Clin. Gastroenterol. Hepatol. 6(2), 159–164 (2008).
  • Spechler SJ. Barrett’s esophagus: clinical issues. Gastrointest. Endosc. Clin. N. Am. 21(1), 1–7 (2011).
  • Dent J. Barrett’s esophagus: a historical perspective, an update on core practicalities and predictions on future evolutions of management. J. Gastroenterol. Hepatol. 26(Suppl. 1), 11–30 (2011).
  • Bennett C, Vakil N, Bergman J et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143(2), 336–346 (2012).
  • Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344(8936), 1533–1536 (1994).
  • Dar MS, Goldblum JR, Rice TW, Falk GW. Can extent of high grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 52(4), 486–489 (2003).
  • Weinstein WM, Ippoliti AF. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest. Endosc. 44(1), 91–95 (1996).
  • Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 104(4), 816–824 (2009).
  • Hahn HP, Blount PL, Ayub K et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am. J. Surg. Pathol. 33(7), 1006–1015 (2009).
  • Kelty CJ, Gough MD, Van Wyk Q, Stephenson TJ, Ackroyd R. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 42(11), 1271–1274 (2007).
  • Gatenby PA, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand. J. Gastroenterol. 43(5), 524–530 (2008).
  • Chandrasoma P. Pathophysiology of Barrett’s esophagus. Semin. Thorac. Cardiovasc. Surg. 9(3), 270–278 (1997).
  • Byrne J, Bhatnagar S, Hamid B, Armstrong GA, Attwood SE. Comparative study of intestinal metaplasia and mucin staining at the gastric cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am. J. Gastroenterol. 94(1), 98–103 (1999).
  • Bhat S, Coleman HG, Yousef F et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J. Natl Cancer Inst. 103(13), 1049–1057 (2011).
  • Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 131(5), 1392–1399 (2006).
  • Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 119(2), 333–338 (2000).
  • Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology 129(6), 1825–1831 (2005).
  • Rex DK, Cummings OW, Shaw M et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125(6), 1670–1677 (2003).
  • Kulig M, Nocon M, Vieth M et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J. Clin. Epidemiol. 57(6), 580–589 (2004).
  • Attwood SE, Lundell L, Hatlebakk JG et al. Medical or surgical management of GERD patients with Barrett’s esophagus: the LOTUS trial 3-year experience. J. Gastrointest. Surg. 12(10), 1646–1654; discussion 1654 (2008).
  • Spechler SJ. Clinical practice. Barrett’s esophagus. N. Engl. J. Med. 346(11), 836–842 (2002).
  • Rossi M, Barreca M, de Bortoli N et al. Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann. Surg. 243(1), 58–63 (2006).
  • Wani S, Mathur S, Sharma P. How to manage a Barrett’s esophagus patient with low-grade dysplasia. Clin. Gastroenterol. Hepatol. 7(1), 27–32 (2009).
  • Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 105(7), 1523–1530 (2010).
  • Wani S, Falk GW, Post J et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 141(4), 1179–1186, 1186.e1 (2011).
  • de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut 59(8), 1030–1036 (2010).
  • Hernandez JC, Reicher S, Chung D et al. Pilot series of radiofrequency ablation of Barrett’s esophagus with or without neoplasia. Endoscopy 40(5), 388–392 (2008).
  • Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett’s esophagus. Am. J. Gastroenterol. 88(11), 1832–1836 (1993).
  • Pech O, Ell C. Endoscopic therapy of Barrett’s esophagus. Curr. Opin. Gastroenterol. 25(5), 405–411 (2009).
  • Attwood SE, Chatterjee S. Argon plasma coagulation in Barrett’s esophagus: the most widely available technique. In: Endoscopic Therapy for Barrett’s Esophagus. Sampliner RE (Ed.). Springer, NY, USA, 21–41 (2009).
  • Goldberg SN. Radiofrequency tumor ablation: principles and techniques. Eur. J. Ultrasound 13(2), 129–147 (2001).
  • Nath S, Haines DE. Biophysics and pathology of catheter energy delivery systems. Prog. Cardiovasc. Dis. 37(4), 185–204 (1995).
  • Wolfsen HC, Crook JE, Krishna M et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s Esophagus. Gastroenterology 135(1), 24–31 (2008).
  • Pech O, Gossner L, Manner H et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy 39(7), 588–593 (2007).
  • Peters FP, Brakenhoff KP, Curvers WL et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus. Gastrointest. Endosc. 67(4), 604–609 (2008).
  • Mino-Kenudson M, Hull MJ, Brown I et al. EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest. Endosc. 66(4), 660–666 (2007).
  • Tharavej C, Hagen JA, Peters JH et al. Predictive factors of coexisting cancer in Barrett’s high-grade dysplasia. Surg. Endosc. 20(3), 439–443 (2006).
  • Shaheen NJ, Fleischer DE, Eisen GM et al. Durability of epithelial reversion after radiofrequency ablation: follow-up of the AIM dysplasia trial. Gastroenterology 138(5 Suppl. 1), S16–S17 (2010).
  • Hur C, Choi SE, Rubenstein JH et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology 143(3), 567–575 (2012).
  • Fleischer DE, Odze R, Overholt BF et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett’s esophagus. Dig. Dis. Sci. 55(7), 1918–1931 (2010).
  • Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest. Endosc. 68(5), 867–876 (2008).
  • Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 61(7), 970–976 (2012).
  • Sharma VK, Wang KK, Overholt BF et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest. Endosc. 65(2), 185–195 (2007).
  • Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost–utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology 136(7), 2101–2114.e1 (2009).
  • Bulsiewicz WJ, Shaheen NJ. The role of radiofrequency ablation in the management of Barrett’s esophagus. Gastrointest. Endosc. Clin. N. Am. 21(1), 95–109 (2011).
  • Titi M, Overhiser A, Ulusarac O et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett’s esophagus. Gastroenterology 143(3), 564.e1–566.e1 (2012).
  • Zhou C, Tsai TH, Lee HC et al. Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). Gastrointest. Endosc. 76(1), 32–40 (2012).
  • Tsai TH, Zhou C, Tao YK et al. Structural markers observed with endoscopic 3-dimensional optical coherence tomography correlating with Barrett’s esophagus radiofrequency ablation treatment response (with videos). Gastrointest. Endosc. 76(6), 1104–1112 (2012).
  • Pouw RE, Wirths K, Eisendrath P et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin. Gastroenterol. Hepatol. 8(1), 23–29 (2010).
  • Bronner MP, Overholt BF, Taylor SL et al.; International Photodynamic Therapy Group for High-Grade Dysplasia in Barrett’s Esophagus. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett’s esophagus with high-grade dysplasia. Gastroenterology 136(1), 56–64; quiz 351 (2009).
  • Pouw RE, Gondrie JJ, Rygiel AM et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am. J. Gastroenterol. 104(6), 1366–1373 (2009).
  • Peters F, Kara M, Rosmolen W et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy 37(5), 418–424 (2005).
  • Goers TA, Leão P, Cassera MA, Dunst CM, Swanström LL. Concomitant endoscopic radiofrequency ablation and laparoscopic reflux operative results in more effective and efficient treatment of Barrett esophagus. J. Am. Coll. Surg. 213(4), 486–492 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.